Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.

British journal of clinical pharmacology - 1 Oct 1999

Brynne N, Svanström C, Aberg-Wistedt A, Hallén B, Bertilsson L

Abstract excerpt

AIMS: To investigate the change in disposition of tolterodine during coadministration of the potent cytochrome P450 2D6 (CYP2D6) inhibitor fluoxetine. METHODS: Thirteen patients received tolterodine l-tartrate 2 mg twice daily for 2.5 days, followed by fluoxetine 20 mg once daily for 3 weeks and then concomitant administration for an additional 2.5 days. They were characterized as extensive metabolizers (EM1 with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzhydryl Compounds
Share to Cresols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Cytochrome P-450 CYP2D6 Inhibitors

Share to Fluoxetine

Share to Hydroxylation

Share to Muscarinic Antagonists

Share to Selective Serotonin Reuptake Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 10583026
DOI: 10.1046/j.1365-2125.1999.00051.x
PMCID: PMC2014382

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.PMID 10583026Read ↗

Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.Semantic proximity Read ↗

Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.Semantic proximity Read ↗

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.Semantic proximity Read ↗

Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.Semantic proximity Read ↗

Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations.Semantic proximity Read ↗

Safety and side effect profile of fluoxetine.Semantic proximity Read ↗

Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.Semantic proximity Read ↗

Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.Semantic proximity Read ↗

Unsuspected poor metabolizer phenotypes of fluoxetine in bioavailability/bioequivalence studies from an indian population perspective. Retrospective pharmacokinetic data evaluation.Semantic proximity Read ↗

Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers.Semantic proximity Read ↗

Trends in Tramadol: Pharmacology, Metabolism, and Misuse.Semantic proximity Read ↗

Inhibition by fluoxetine of cytochrome P450 2D6 activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.